David Berman
Equibles does not estimate personal net worth.
About David Berman
Immunocore Holdings plc reported in an 8-K filed January 30, 2026 that David Berman resigned as Head of Research & Development, effective February 27, 2026. The same filing states: “Dr. Berman’s decision to resign was not the result of any disagreement between Dr. Berman and the Company or any matter relating to the Company’s operations, policies, or practices.” The proxy statement of Immunocore Holdings plc reports total compensation of $4,278,988 for David Berman in fiscal 2025, including a base salary of $540,000. Disclosed compensation is on record for 3 fiscal years.
“On January 27, 2026, David Berman notified Immunocore Holdings plc (the "Company") of his decision to resign as Head of Research & Development of the Company, effective as of February 27, 2026, in order to pursue another opportunity.”
“Dr. Berman’s decision to resign was not the result of any disagreement between Dr. Berman and the Company or any matter relating to the Company’s operations, policies, or practices.”
Affiliation history
-
Immunocore Holdings plc (IMCR)
Proxy statement
Start not stated–2026-02-27
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Immunocore Holdings plc (IMCR) | M.D., Ph.D. Former Executive Vice President, Head of Research & Development | $540,000 | $4,278,988 |
| 2024 | Immunocore Holdings plc (IMCR) | M.D., Ph.D. Executive Vice President, Head of Research & Development | $535,833 | $5,481,495 |
| 2023 | Immunocore Holdings plc (IMCR) | M.D., Ph.D. Executive Vice President, Head of Research & Development | $515,000 | $4,396,622 |
Recent activity
-
Executive change Resigned: Head of Research & Development
“Dr. Berman’s decision to resign was not the result of any disagreement between Dr. Berman and the Company or any matter relating to the Company’s operations, policies, or practices.”
Immunocore Holdings plc (IMCR)